Video Author: Neil Osterweil Publish date: December 12, 2018
SAN DIEGO – Adding the anti-CD38 monoclonal antibody to lenalidomide and dexamethasone significantly decreased 30-month risk of progression.
News Author: Neil Osterweil Publish date: December 12, 2018
SAN ANTONIO – Circulating tumor cell counts rival clinician choice for determining whether to prescribe hormonal therapy or chemotherapy, investiga...
News Author: Neil Osterweil Publish date: December 12, 2018
SAN DIEGO—In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger than ...
News Author: Neil Osterweil Publish date: December 11, 2018
SAN ANTONIO – Disseminated tumor cells detected in marrow at diagnosis or primary surgery for early breast cancer are associated with worse clinica...
News Author: Neil Osterweil Publish date: December 11, 2018
SAN DIEGO – Survival and safety outcomes were better with ibrutinib and rituximab than with the FCR regimen.
News Author: Neil Osterweil Publish date: December 7, 2018
SAN ANTONIO – For patients with ADH, DCIS, or LCIS, one-fourth of the standard dose reduced risk for both invasive disease/DCIS and contralateral b...
News Author: Neil Osterweil Publish date: December 7, 2018
SAN DIEGO—A recurrent mutation in BCL2, the therapeutic target of venetoclax, appears to be a major contributor to drug resistance in patients with...
Video Author: Neil Osterweil Publish date: December 6, 2018
SAN ANTONIO – For patients with ER-positive, HER2-negative metastatic breast cancer, the use of CTC counts can help clinicians decide between order...
News Author: Neil Osterweil Publish date: December 6, 2018
SAN ANTONIO – Women with breast intraepithelial neoplasms who took tamoxifen for 3 years at a dose of 5 mg per day had a 50% reduction in risk of r...
News Author: Neil Osterweil Publish date: December 6, 2018
SAN ANTONIO – The 3-year invasive disease-free recurrence was 88.3% for patients with residual disease treated with T-DM1 versus 77.0% with trastuz...
News Author: Neil Osterweil Publish date: December 5, 2018
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Video Author: Neil Osterweil Publish date: December 5, 2018
SAN ANTONIO – For the primary endpoint of invasive disease-free survival, T-DM1 was associated with a hazard ratio of 0.50.
News Author: Neil Osterweil Publish date: December 5, 2018
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
News Author: Neil Osterweil Publish date: December 5, 2018
SAN DIEGO—A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy w...
News Author: Neil Osterweil Publish date: December 4, 2018
SAN DIEGO—An updated analysis of the JULIET trial showed that tisagenlecleucel produced a high rate of durable responses in adults with relapsed or...
